FGF21 and metabolic dysfunction-associated steatotic liver disease: In addition, FGF21, as an endocrine factor, exerts inhibitory effects against NAFLD by regulating diverse extrahepatic tissues, including adipose tissue, pancreas, and skeletal muscle 24-28.